Naoto Ueno, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses defining the HER2-low breast cancer subtype via immunohistochemical staining. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
